Swiss National Bank Portfolio holdings
The Swiss National Bank (SNB), founded in 1907 and headquartered in Zurich with an office in Bern, is Switzerland’s central bank, responsible for conducting monetary policy, issuing the Swiss franc, and ensuring price stability, while uniquely managing a massive investment portfolio. Unlike most central banks, the SNB is a joint-stock company with shares traded on the SIX Swiss Exchange, owned roughly 55% by public entities like cantons and 45% by private investors, yet it operates independently under federal oversight. It holds over $800 billion in foreign currency reserves as of late 2024—invested in global equities, bonds, and gold—to manage the franc’s value, famously intervening in markets to prevent excessive appreciation, as seen with the 2015 abandonment of the euro peg. Led by Chairman Thomas Jordan until his planned exit in September 2024, the SNB balances its dual role as a monetary authority and a significant global investor, influencing both Swiss and international financial stability.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alibaba
BABA
|
+$133M |
| 2 |
AbbVie
ABBV
|
+$110M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$93.9M |
| 4 |
Amazon
AMZN
|
+$91.8M |
| 5 |
Otis Worldwide
OTIS
|
+$84M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$226M |
| 2 |
RTN
Raytheon Company
RTN
|
+$145M |
| 3 |
WBC
WABCO HOLDINGS INC.
WBC
|
+$51.2M |
| 4 |
Newmont
NEM
|
+$50.7M |
| 5 |
Yum! Brands
YUM
|
+$33.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.6% |
| 2 | Healthcare | 15.16% |
| 3 | Consumer Discretionary | 12.49% |
| 4 | Communication Services | 10.41% |
| 5 | Industrials | 8.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
EGRX
1976
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $1.24M | ﹤0.01% |
25,900
+4,700
| +22% | +$234K |
|
1977
Dave & Buster's
PLAY
$370M
| $1.24M | ﹤0.01% |
93,173
+33,400
| +56% | +$445K |
|
|
BMTC
1978
DELISTED
Bryn Mawr Bank Corp
BMTC
| $1.24M | ﹤0.01% |
44,900
+5,900
| +15% | +$160K |
|
1979
PC Connection
CNXN
$2.04B
| $1.24M | ﹤0.01% |
26,700
+3,700
| +16% | +$156K |
|
|
QUOT
1980
DELISTED
Quotient Technology Inc
QUOT
| $1.24M | ﹤0.01% |
168,800
+22,100
| +15% | +$148K |
|
|
ARR
1981
Armour Residential REIT
ARR
$2.37B
| $1.23M | ﹤0.01% |
26,282
+3,440
| +15% | +$144K |
|
|
ALX
1982
Alexander's
ALX
$1.4B
| $1.23M | ﹤0.01% |
5,100
+600
| +13% | +$161K |
|
1983
Ingles Markets
IMKTA
$1.68B
| $1.23M | ﹤0.01% |
28,500
+4,100
| +17% | +$166K |
|
|
CIO
1984
DELISTED
City Office REIT
CIO
| $1.23M | ﹤0.01% |
121,900
+16,100
| +15% | +$149K |
|
|
KRA
1985
DELISTED
Kraton Corporation
KRA
| $1.22M | ﹤0.01% |
70,800
+10,100
| +17% | +$137K |
|
1986
Corbus Pharmaceuticals
CRBP
$195M
| $1.22M | ﹤0.01% |
+4,853
| New | +$981K |
|
1987
AnaptysBio
ANAB
$1.66B
| $1.22M | ﹤0.01% |
54,600
+7,200
| +15% | +$132K |
|
1988
Center Bancorp
CNOB
$1.81B
| $1.22M | ﹤0.01% |
75,700
+9,900
| +15% | +$141K |
|
|
FSP
1989
Franklin Street Properties
FSP
$46.4M
| $1.22M | ﹤0.01% |
239,463
+31,500
| +15% | +$167K |
|
|
EBIX
1990
DELISTED
Ebix Inc
EBIX
| $1.22M | ﹤0.01% |
54,500
+7,200
| +15% | +$148K |
|
|
AVTA
1991
DELISTED
Avantax, Inc. Common Stock
AVTA
| $1.22M | ﹤0.01% |
106,600
+11,700
| +12% | +$147K |
|
1992
Evolent Health
EVH
$527M
| $1.22M | ﹤0.01% |
170,700
+24,200
| +17% | +$162K |
|
|
PRVB
1993
DELISTED
Provention Bio, Inc. Common Stock
PRVB
| $1.22M | ﹤0.01% |
+86,100
| New | +$1.09M |
|
|
CKH
1994
DELISTED
Seacor Holdings Inc.
CKH
| $1.21M | ﹤0.01% |
42,800
+5,600
| +15% | +$153K |
|
|
ODT
1995
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
| $1.21M | ﹤0.01% |
28,600
+900
| +3% | +$29.1K |
|
1996
Ecovyst
ECVT
$1.1B
| $1.21M | ﹤0.01% |
91,400
+12,000
| +15% | +$141K |
|
|
SWTX
1997
DELISTED
SpringWorks Therapeutics
SWTX
| $1.21M | ﹤0.01% |
+28,800
| New | +$1.02M |
|
1998
Anika Therapeutics
ANIK
$283M
| $1.2M | ﹤0.01% |
31,900
+4,200
| +15% | +$138K |
|
1999
Rhythm Pharmaceuticals
RYTM
$7.99B
| $1.2M | ﹤0.01% |
54,000
-5,600
| -9% | -$109K |
|
2000
Quanterix
QTRX
$135M
| $1.2M | ﹤0.01% |
43,800
+16,600
| +61% | +$419K |
|
Similar funds
Swiss National Bank's Q2 2020 Portfolio in Review
As of Q2 2020, Swiss National Bank held 2,599 positions worth $118B, up 26% from $94.2B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Swiss National Bank's Q2 2020 filing shows 119 new, 2,134 increased, 181 reduced and 161 closed positions. Its largest new stake was Otis Worldwide: 1,621,054 shares worth $92.2M. The largest sale was Allergan plc, an estimated $226M.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 24% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Swiss National Bank's largest Q2 2020 buy was Otis Worldwide: 1,621,054 shares worth $92.2M.
- Swiss National Bank added most to Alibaba in Q2 2020, an estimated $133M increase.
- Swiss National Bank's biggest Q2 2020 reduction was Newmont, cutting an estimated $50.7M.
- Swiss National Bank fully exited Allergan plc in Q2 2020, selling an estimated $226M.
- Swiss National Bank's ten largest holdings make up 24% of its $118B portfolio in Q2 2020.
- Swiss National Bank opened 119 new positions and closed 161 in Q2 2020.
- Swiss National Bank's portfolio value rose 26% quarter-over-quarter to $118B.
Based on Swiss National Bank's 13F filing for Q2 2020, filed 5 Aug 2020.